METHYLPREDNISOLON
| StockNo |
Product description |
Status |
| EB0280-446-04 |
METHYLPREDNISOLON
4 MG X 20 TABL |
 |
| EB0280-446-07 |
METHYLPREDNISOLON
AMPOULE 8 MG/2 ML + SOLUTION |
|
| EB0280-446-08 |
METHYLPREDNISOLON
AMPOULE 20 MG/2 ML + SOLUTION |
|
| EB0280-446-09 |
METHYLPREDNISOLON
AMPOULE 40 MG/2 ML + SOLUTION |
|
| EB0280-446-10 |
METHYLPREDNISOLON
AMPOULE 125 MG/5 ML + SOLUTION |
|
-
- COMPOSITION:
6-methylprednisolon hemisuccinate sodium - 8 mg/2 ml; 20 mg/2
ml; 250 mg/2 ml lyophilized powder in one ampoule. Tablets 4 mg.
ACTION:
A corticosteroid preparation of synthetic origin. It possesses a
strong antiphlogistic, antiallergic and antishock action, and a weak
mineralcorticoid activity in comparison with the preparations of
this pharmacologic group.
The sodium salt of Methylprednisolon is highly soluble in water,
well absorbed and has longer and more rapid effect at parenteral
application in comparison with hydrocortison and prednisolon.
INDICATIONS:
All indications of glucocorticoid therapy requiring urgent
intervention: status asthmaticus, severe allergic shocks of
different origin, thyreotoxic and Addison's crises, myocardial
infarction, acute hematolonic diseases, acute diseases of hepatic
parenchyma, and as an additional treatment of bacterial infections,
toxicosis and intoxications.
CONTRAINDICATIONS:
The following contraindications are present for systemic therapy
with Methylprednisolon: diabetes mellitus, peptic ulcer, syphilis,
mental disorders, heavy osteoporosis, amoebiasis, systemic mycoses,
varicella, glaucoma, herpes simplex and herpes zoster, Izenko-Cushing's
disease.
The preparation should be applied carefully during pregnancy,
advanced age, severe hypertension and cardiovascular insufficiency.
SIDE EFFECTS:
The prolonged application may lead to: obesity, hirsutism, steroid
acne, disurbances in the menstrual cycle, osteoporosis, Izenko-Cushing's
symptom complex, peptic ulcers in the digestive tract or perforation
of existing ulcers, hemorrhage pancreatitis, hyperglycemia or
manifestation of a latent diabetes, increased blood coagulation
capacity, mental disturbances, increased risk of infections and
inhibition of immune processes. |
DRUG INTERACTIONS:
The combination with antihistamine preparations, barbiturates,
diphenine and riphampicine leads to lower hormonal activity, while
diphenine causes hyperglycemia as well. A mutual potentiation of the
principal effects of the preparations may be observed after combined
application with cardiac glucosides and stimulators of CNS. ACTH
enhances the effect of Methylpresnisolon. The simultaneous
application with antiacid drugs, salicylates, butadion and
indomethacin increases the risk of development of gastric peptic
ulcer. Methylprednisolon weakens the effects of coumarine
anticoagulants. The immunopressor and anticancer preparations
enhance the activity of Methylprednisolon.
PRECAUTIONS:
The solution obtained from the dry substance should be used
immediately. It should not be mixed with other preparations in one
syringe and other infusion solutions or systems, except 5 % glucose
solution, should not be used.
DOSAGE AND ADMINISTRATION:
The preparation is applied parenterally, intramuscularly or
intravenously.
Adults - the average dose is from 40 to 80 mg once or several times
a day, if needed the daily dose may reach 30 mg/kg b.w.
Children - 40-80 mg daily.
The interval between the separate injections is from 30 min to 24 h.
MEDICINAL FORM AND PACKAGE:
Ampoules with lyophilized powder from 2 ml together with a solvent
for each ampoule.
STORAGE:
At moderate temperature (15-30° C).
EXPIRY:
5 (five) years.
|
